
RNAC Stock Forecast & Price Target
RNAC Analyst Ratings
Bulls say
Cartesian Therapeutics is well-positioned in the emerging in vivo CAR-T landscape, with plans to advance multiple internally-developed anti-BCMA CAR constructs and CAR-T cell engagers through their partnership with WestGene, positioning the company advantageously in the sector. The company's Phase 2 and 3 trials for Descartes-08 in MG and myositis are on track for data readouts in 1H27, and its differentiated profile compared to DNA-based CAR-T therapies make it a promising option for treating autoimmune diseases. Additionally, Cartesian's in-house mRNA manufacturing capabilities provide a competitive advantage in terms of cost structure, further supporting the commercial case for Descartes-08. However, as with any drug development company, Cartesian faces standard risks and uncertainties associated with clinical trials and regulatory approval that may affect its success in the market.
Bears say
Cartesian Therapeutics is a clinical-stage biopharmaceutical company pioneering a cell therapy approach using mRNA to treat autoimmune diseases. While the Phase 3 data for Descartes-08 in treatment-resistant myasthenia gravis is expected in 2027, there are concerns about the potential for safety issues and limited durability of current MG treatments. Additionally, current approved Txs for MG are suppressive rather than curative, creating a need for new therapies with less frequent dosing and potential for functional cures.
This aggregate rating is based on analysts' research of Cartesian Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
RNAC Analyst Forecast & Price Prediction
Start investing in RNAC
Order type
Buy in
Order amount
Est. shares
0 shares